Provide medicinal products derived from plasma and recombinant proteins, ensuring their availability while helping to improve patient care pathways thanks to LFB's commitment to caregivers and patient associations.



Triple LFB's fractionation capacity



Double the number of production sites approved by international health authorities by 2030



Present 100% of strategic product development projects to relevant patient associations by 2026

Our CSR strategy, is our Raison d'être in action

"LFB, EXPERTISE

COMMITTED

TO LIFE"

## COMMITTING TO OUR TEAMS

Foster a work environment where safety, well-being, and development are our core priorities, building on an inclusive corporate culture founded on commitment and a shared desire to work together.



Reduce by 80% the number of work accidents with lost time by 2030 (vs 2023)



Enable 100% of employees to have a development and expertise plan by 2030

Raise awareness among 100% of employees to CSR issues by 2030

## RESPECTING THE ENVIRONMENT

Reduce the carbon and environmental footprint of our activities, adapt our value chain and operations to climate challenges, preserve water resources, and optimise our production processes.



Reduce GHG emissions by 43% by 2030 for scopes 1, 2 and 3 (vs 2022)



Reduce water consumption by 10% by 2030 (vs 2022)



Conduct a carbon assessment of medicines whose sales represent 80% of our revenue by 2030

## **ACTING WITH INTEGRITY**

**Embody exemplary** behaviour through responsible and transparent practices, placing ethics at the heart of our decisions and our impact.



Train 100% of employees on the LFB Code of Conduct by 2028



Give priority to suppliers and service providers that are aligned with our CSR commitments



Ensure that, by 2030, 90% of active donors have a good or excellent donation experience at our collection centres

**OUR EVIDENCE** 



